Dana-Farber Cancer Insitute is a clinical research site located in Boston, Massachusetts, United States 02215.
Crixeo Health Trust Score: 75/100 (FAIR). This profile has not yet been claimed by the site owner.
Dana-Farber Cancer Insitute has participated in 11 clinical trials with 3 currently active.
Therapeutic areas: Neoplasms, Solid Tumor, Adult, Metastatic Breast Cancer.
Sponsors: Pfizer, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), Dana-Farber Cancer Institute.
Trust Score: 75/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
Dana-Farber Cancer Insitute has a Crixeo Trust Score of 75/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Dana-Farber Cancer Insitute has 11 clinical trials on record, with 3 currently active. Their work covers Neoplasms, Solid Tumor, Adult, Metastatic Breast Cancer.
Yes — Dana-Farber Cancer Insitute holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.